A carregar...
Publicação
Vedolizumab and new‐onset spondyloarthritis: debunking the myth
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 131.33 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Despite an increased understanding of the etiopathogenesis of Inflammatory Bowel Disease (IBD), prevention or cure remains a distant aspiration and current treatment approaches often do not achieve long‐term disease remission. An additional complexity is that IBD can also be associated with a range of extra‐intestinal manifestations (EIMs). Among these EIMs, peripheral and axial rheumatological manifestations are perhaps the most prevalent, grouped under the term spondyloarthritis (SpA). The presentation of SpA can be before or after IBD diagnosis and presents several unique challenges. Notably, the presence of SpA can significantly impact on quality of life for patients and influence therapeutic decision‐making.
Descrição
Palavras-chave
Adverse effects Extra‐intestinal manifestations Inflammatory bowel disease Treatment
Contexto Educativo
Citação
Editora
Wiley